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Abstract: Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are 
effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA 
approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes 
with Sp1 transcription factor binding to its target sites (GC box). HDACi, on the other 
hand, modulate the activity of class I and II histone deacetylases. They mediate their 
protective function, in part, by regulating the acetylation status of histones or transcription 
factors, including Sp1, and in turn chromatin accessibility to the transcriptional machinery. 
Because these two classes of structurally and functionally diverse compounds mediate 
similar therapeutic functions, we investigated whether they act on redundant or synergistic 
pathways to protect neurons from oxidative death. Non-protective doses of each of the 
drugs do not synergize to create resistance to oxidative death suggesting that these distinct 
agents act via a similar pathway. Accordingly, we found that protection by MTM and 
HDACi is associated with diminished expression of the oncogene, Myc and enhanced 
expression of a tumor suppressor, p21waf1/cip1. We also find that neuroprotection by MTM 
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or Myc knockdown is associated with downregulation of class I HDAC levels. Our results 
support a model in which the established antitumor drug MTM or canonical HDACi act via 
distinct mechanisms to converge on the downregulation of HDAC levels or activity 
respectively. These findings support the conclusion that an imbalance in histone acetylase 
and HDAC activity in favor of HDACs is key not only for oncogenic transformation, but 
also neurodegeneration.  
Keywords: mithramycin A; HDAC inhibition; Myc; neurons; oxidative stress 
 
1. Introduction 
Extensive studies from cell culture and human postmortem tissue reveal a mechanistic connection 
between oncogenesis and acute and chronic neurodegeneration in the CNS. The ability of transforming 
stimuli (e.g., SV40 T antigen) to induce death of neurons led to the notion that clonal expansion that 
normally accompanies carcinogenesis in dividing cells has been supplanted by clonal deletion in post 
mitotic neurons to avoid tumors from disrupting CNS circuitry during aging [1,2]. Support for this 
concept has grown as many classical anti-tumor compounds such as mithramycin A (MTM) and 
histone deacetylase inhibitors (HDACi) have been shown to be broadly effective in rodent models of 
neurological disease. 
MTM is a gene selective Sp1 inhibitor that has long been used as a chemotherapeutic agent. Its use 
was highlighted in a screen for compounds effective in inhibiting tumor cell growth without affecting 
normal cells [3]. It is also neuroprotective in vitro and in vivo models of neurodegeneration [4-8]. It 
rapidly enters into the cells, binds to GC rich DNA sequences, thus displacing the Sp1 transcription 
factor from its binding sites on the promoters of oncogenes such as Myc to inhibit their expression. 
These effects contribute to its ability to kill cancer cells as well as protect neurons against toxic insults. 
Indeed, we have recently shown that MTM mediated knockdown of oncogenes including Myc protects 
against oxidative stress-mediated neuronal death in vitro or in fly and rodent models of Huntington’s 
disease in vivo [2]. 
HDACi are small molecules that interfere with the ability of histone deacetylases (HDAC) to 
remove acetyl groups from histones and other cellular proteins. They are classified into several groups 
based on their chemical structure and which HDAC class they target. For example, butyrate, apicidin 
and MS-275 are structurally diverse compounds that selectively inhibit Class I HDACs [9], which 
includes the predominantly nuclear HDACs: HDAC1, HDAC2, HDAC3 and HDAC8. The dynamic 
state of chromatin and the accessibility of gene promoters to the transcriptional machinery are 
dependent on the balance between histone acetyltransferase (HAT) and HDAC activity. Defects in the 
regulation in the interplay between HAT and HDAC function can lead to development of many 
cancers as well as to neurodegenerative disease. For example, HDAC2 and HDAC3 are over-expressed 
in multiple forms of cancer [10-13], and contribute as well to neurodegeneration [14-16]. HDACi are 
not only therapeutically effective against cancer, but they are moving toward human clinical trials for 
neurodegeneration [17,18] and stroke [17-20]. 
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Considering the effectiveness of both MTM and HDACi in killing cancer cells but protecting 
neurons, we investigated whether they protect against oxidative stress-induced neuronal death by 
targeting a convergent pathway. Indeed, we show that it is not only sufficient to inhibit the Class I 
nuclear HDACs to mediate neuroprotection against oxidative stress, but also that the pathways targeted 
by HDACi and MTM are overlapping. Specifically, protection both MTM and HDACi is associated 
with inhibition of the expression of the oncogene Myc and induction of the tumor suppressor 
p21waf1/cip1. We also show that MTM or Myc knockdown can inhibit the expression of class I HDACs. 
Our results suggest that MTM and HDACi target pathways that converge at the intersection of cancer 
and neurodegeneration.  
2. Experimental Section 
Cell Culture: Immature primary cortical neurons were obtained from fetal Sprague Dawley rats 
[embryonic day 17 (E17)] as previously described [21]. 
Cell Viability: For cytotoxicity studies, immature primary cortical neurons (E17) were isolated as 
described above and plated at a density of one million cells/mL in 96-well plates. The next day, cells 
were rinsed with warm PBS and then placed in medium containing the glutamate analogue HCA  
(5 mM). HCA was diluted from 100-fold concentrated solutions that were adjusted to pH 7.5. MTM 
(7.5 nM or 300 nM), mithramycin SDK (SDK; 7.5 nM or 75 nM), sodium butyrate (50 µM or 5 mM), 
TSA (0.66 μM), apicidin (10 nM) and MS-275 (100 nM) were added at the time of HCA treatment and 
were present throughout the experiment. MTM and sodium butyrate were prepared as 10 mM or 0.5M 
solutions respectively and serial dilutions were used to arrive to the desired concentration. The next 
day, cell viability was assessed by the MTT assay (Promega) [22]. 1way ANOVA followed by the 
Dunnett post test was used to measure statistical significance. p < 0.05 was considered to be 
statistically significant.  
RNA extraction and Real Time PCR: Total RNA was prepared from immature primary cortical 
neurons (E17) using the NucleoSpin RNA II Kit (MACHEREY-NAGEL) according to the 
manufacturer’s protocol. Real-time PCRs were performed as a duplex reaction using a Myc 
(Rn00561507_m1), p21waf1/cip1 (Rn01427989_s1), HDAC1 (Rn02114316_gH), HDAC2 
(Rn01193634_g1), HDAC3 (Rn00584926_m1) and HDAC8 (Rn01419050_m1) gene expression assay 
(Applied Biosystems), which use a FAM-labeled probe, and a β-actin gene expression assay, which 
uses a VIC-labeled probe (Applied Biosystems) so that gene amplification could be normalized to  
β-actin. These experiments were performed using a 7500 Real Time PCR System (Applied 
Biosystems) using standard PCR protocol and amplification conditions. One-way ANOVA followed 
by the Dunnett post test were performed to measure statistical significance. p < 0.05 was considered to 
be statistically significant. 
Immunoblot analysis: Whole cell proteins were extracted in RIPA-B buffer (1% Triton X-100, 1% 
SDS, 50 mM Tris-Cl, pH 7.4, 500 mM NaCl and 1 mM EDTA). Samples were boiled in Laemmli 
buffer and electrophoresed under reducing conditions on NuPAGE® Novex 4–12% Bis-Tris Gel 
polyacrylamide gels (Invitrogen). Proteins were transferred to a nitrocellulose membrane (Bio-Rad) by 
electroblotting. Nonspecific binding was inhibited by incubation in Odyssey blocking buffer (LI-COR 
Biosciences). Antibodies against c-Myc (1472-1; Epitomics), p21waf1/cip1 (OP-76; Calbiochem), 
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HDAC1 (PA1-860; Thermo Scientific), HDAC2 (1603-1; Epitomics), HDAC3 (2246-1; Epitomics), 
HDAC8 (sc-11405; Santa Cruz Biotechnology) and β-actin (AC-74; Sigma-Aldrich) were diluted 
1:1000, 1:1000; 1:2000; 1:2000; 1:1000; 1:1000 and 1:10,000, respectively, in odyssey blocking buffer 
and the membranes were incubated overnight at 4 °C. Fluorophore-conjugated Odyssey IRDye-680 or 
IRDye-800 secondary antibody (LI-COR Biosciences) was used at 1:10,000 dilution followed by 
incubation for 1 hour at room temperature. Finally, proteins were detected using an Odyssey infrared 
imaging system (LI-COR Biosciences). 
Myc ShRNA know down: Two Myc (NM_012603) ShRNA clones (TRCN0000039641: 5' AAACC 
CAGGGCTGCCTTGGAAAAG 3' and TRCN0000039641: 5' AAACCCAGGGCTGCCTTGGAA 
AAG 3'; Open Biosystems) and Non-Target shRNA Control Vector (Sigma) were introduced into 
immature primary cortical neurons (E17) using the Amaxa Rat neuron Nucleofector Kit as directed by 
the manufacturer’s protocol (Lonza). The next day, Myc knockdown was confirmed by whole cell 
lysate western blots.  
Statistical Analysis: 1way or 2way ANOVA followed by the Dunnett or Bonferroni post tests 
respectively were used to measure statistical significance. p < 0.05 was considered to be statistically 
significant. 
3. Results 
MTM and HDACi protect the central nervous system (CNS) from both chronic and acute insults. 
For example, they are among the most effective therapeutic compounds tested to date in animal models 
of Huntington’s disease [2,5,18,23] as well as in stroke [17,19,20]. Because oxidative stress is a feature 
of most neurodegenerative diseases, we utilized an in vitro model of neuronal oxidative death to test 
whether these two structurally divergent classes of antitumor compounds are neuroprotective via 
similar mechanisms. When immature cortical neurons (E17) are continuously exposed to glutamate [or 
a glutamate analogue, homocysteic acid (HCA)], they die via competitive inhibition of cystine 
transport [21]. Reduced intracellular cyst(e)ine leads to depletion of the antioxidant glutathione. Cell 
death attributable to glutathione depletion has features of apoptosis and can be completely prevented 
by classical antioxidants [21]. MTM (300 nM), its more potent and less toxic structural analog SDK 
(75 nM), sodium butyrate (5 mM), apicidin (10 nM), and MS-275 (100 nM)} protect post mitotic 
cortical neurons from oxidative stress-induced neuronal death (Figure 1A). They appear to mediate 
neuroprotection by normalizing the transcriptional profile of neurons in response to oxidative stress [2] 
(data not shown). Specifically, MTM promotes neuroprotection, in part, by inhibiting the expression of 
oncogenes such as Myc and by promoting the expression of tumor suppressors such as p21waf1/cip1. This 
is due to its ability to displace the Sp1 transcription factor from its binding sites (GC boxes) on the 
promoter of Myc without affecting its binding to the promoter of p21waf1/cip1 [2]. Sodium butyrate, 
apicidin and MS-275, on the other hand, are class I selective HDAC (HDAC1, 2, 3 and 8) inhibitors. 
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Figure 1. MTM, sodium butyrate, apicidin and MS-275 protect immature cortical neurons 
against oxidative death by targeting overlapping pathways.  
 
(A): MTM (300 nM), SDK (75 nM, the MTM analog that binds to DNA), sodium butyrate (5 mM), 
apicidin (10 nM) and MS-275 (100 nM) protect immature primary cortical neurons (E17) from 
oxidative stress, whereas PreB (300 nM, the MTM analog that does not bind to DNA) does not.  
(B and C): No increase in cell survival is detected in response to oxidative stress in cells treated 
with sub-protective doses of MTM (B) or its SDK analog (C) along with sub-protective doses of 
sodium butyrate. Statistical analysis was conducted by 1way ANOVA followed by the Dunnett post 
test. Significant levels compared to HCA (5 mM) treatment alone. * p < 0.05; and ** p < 0.01; and  
*** p < 0.0001. Cell survival experiments were repeated three times. 
To determine whether there is a convergence in the protective pathways targeted by these 
compounds, we treated immature cortical neurons with sub-protective doses of MTM (7.5 nM) or its 
analog SDK (7.5 nM) plus sodium butyrate (50 µM) and assessed neuronal survival in response to 
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oxidative stress. This strategy was utilized in previous work that identified combinatorial treatments 
for Huntington’s Disease flies [24]. We expected to observe an additive effect on survival if these 
compounds promote protection via independent parallel pathways; on the other hand, if converging 
pathways are affected, no such additive protection should be observed. Indeed, treatment of neurons 
with threshold doses of MTM or its analog SDK plus sodium butyrate does not increase the survival of 
neurons exposed to oxidative stress as compared to either compound alone suggesting the protective 
pathways may be convergent (Figures 1B and C). 
To elucidate putative mechanisms by which the protective pathways converge, we first tested 
whether like MTM, HDAC inhibition affected Myc and p21waf1/cip1levels. We have previously shown 
that MTM induced p21waf1/cip1and repressed Myc levels and that these changes partially contribute to 
MTM’s protective effect [2]. Indeed, we find that like MTM, HDAC inhibition reduced Myc 
expression (Figures 2A, C and D) and induced p21waf1/cip1expression (Figures 2B, C and D). Both of 
these genes are regulated by Sp1 binding to target sites in their promoter. To understand whether the 
change in Myc and p21waf1/cip1 expression in response to HDACi involves alterations of Sp1 occupancy 
at their respective promoters, we performed chromatin immunoprecipitation studies. Previously, we 
have shown that HDACi treatment induces Sp1 acetylation in rat embryonic cortical neurons and 
increases Sp1 binding to GC boxes in electromobility shift assays [23]. We observe that HDACi 
treatment only increased Sp1 occupancy at the p21waf1/cip1promoter, but did not affect its binding to the 
Myc promoter (Figures 2E and F). These results are in agreement with Sp1 being an activator at the 
p21waf1/cip1 promoter [25,26]. Our results suggest that while HDACi downregulate Myc protein 
expression, they do not affect Sp1 occupancy at the Myc promoter. Thus, HDACi may negatively 
affect another transcription factor to modulate Myc expression or alternatively act  
post-transcriptionally to decrease the stability of the protein. Nevertheless, these experiments 
demonstrate that like MTM, HDAC inhibition negatively modulates the oncogene Myc and positively 
affects the tumor suppressor p21waf1/cip1 in post mitotic neurons. 
HDACs are believed modulate tumor progression by silencing tumor suppressor genes. We wanted 
to know whether the antitumor drug MTM negatively modulated HDAC levels and whether this could 
explain the convergence with pharmacological HDACi and underlie some of the protective effects of 
this antitumor drug in post mitotic neurons. Indeed, we found that MTM treatment affects HDAC 
expression levels. We treated cells with protective doses of MTM (300 nM) as well as with the  
non-protective structural analog PreB (300 nM) and performed Real Time PCR monitored message 
levels for the class I HDACs. We focused our attention on class I HDACs since inhibitors of this class 
were sufficient to protect neurons against oxidative stress-induced death (Figure 1A). MTM treatment 
did not significantly affect HDAC1 and HDAC3 mRNA levels (Figures 3A and C), whereas it 
significantly reduced HDAC2, and HDAC8 mRNA levels (Figures 3B and D). As expected, the  
non-protective analog PreB did not have any significant effect on the expression of any of these 
HDACs. We next investigated whether the changes in the expression of these HDACs translated to the 
protein level. Interestingly, even though MTM treatment only significantly affected HDAC2 and 
HDAC3 protein levels, we observe a similar trend in reduction of expression with HDAC1 and 
HDAC8 (Figure 3E and F). To determine whether MTM can act as a global HDACi, we tested whether 
treatment with protective doses of this compound affects global histone H3 acetylation and in turn 
general chromatin accessibility to transcription factors. 
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Figure 2. HDACi like MTM reduce the expression of the Myc oncogene and promote the 
expression of the p21waf1/cip1 tumor suppressor. 
 
(A) Real Time RTPCR analysis reveals that TSA (0.66 µM) significantly inhibits Myc expression 
levels; and (B) induces p21waf1/cip1 expression levels; (C) Western blots reveal that both sodium 
butyrate (5 mM) and TSA (0.66 µM) treatment reduces Myc protein levels and induces p21waf1/cip1 
protein levels; (D) Quantification of the Western blots reveals that the effects on Myc and 
p21waf1/cip1 levels are significant. (E and F) Chromatin immunoprecipitation experiments show that 
HDACi have no effect on Sp1 occupancy on the Myc promoter, whereas they significantly induce 
it at the p21waf1/cip1 promoter. Treatments were conducted for five hours and the experiments were 
repeated three times. Statistical analysis was conducted by 1way ANOVA followed by the Dunnett 
post test. Significant levels compared to control treatment alone. * p < 0.05; and ** p < 0.01; and 
*** p < 0.0001. 
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Figure 3. MTM affects class 1 HDAC expression levels. 
 
Real time RTPCR shows that MTM (300 nM) does not significantly affect HDAC1 (A) and 
HDAC3 (C) expression levels; whereas it significantly reduces HDAC2 (B) and HDAC8 (D) 
expression levels. These changes covary with neuroprotection by MTM as the non-protective 
analog PreB (300 nM) has no effect on the expression of these genes. Cells were treated for five 
hours and the experiments were repeated three times. (E): Western Blots show that MTM treatment 
reduces the protein levels of class 1 HDACs. (F): Quantification of three different western blots 
reveals that only HDAC2 and HDAC3 protein levels are significantly affected by MTM treatment. 
(G): Unlike sodium butyrate (5 mM) and TSA (0.66 µM), MTM does not induce acetylation of 
histone H3. For the western blot experiments, cells were treated with the compounds for 48 hours 
and experiments were repeated three times. Statistical analysis was conducted by 1way ANOVA 
followed by the Dunnett post test. Significant levels compared to control treatment alone.  
*: p < 0.05 and **: p < 0.01 and ***: p < 0.0001. 
We find that unlike HDACi (TSA and sodium butyrate) that MTM did not increase global histone 
H3 acetylation (Figure 3G). This result is in agreement with our observation that only a subset of the 
HDAC proteins is significantly affected by MTM. In addition, we can’t rule out an effect of MTM on 
HAT expression. Taken together, these studies suggest that MTM and sodium butyrate protect neurons 
from oxidative stress by normalizing similar transcriptional responses in neurons. This is achieved in 
part by reducing HDAC protein levels and function as well as by reducing the expression of oncogenes 
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(e.g., Myc) and inducing the expression of tumor suppressor genes (e.g., p21cip1/waf1). The two 
identified mechanisms are most likely linked as HDACs are recruited to the promoters of these two 
genes [27,28]. In addition, Myc has been reported to regulate the expression of some HDAC genes 
including HDAC2 [29]. 
Previously, we have shown that Myc inhibition protects neuron from oxidative stress-induced  
death [2]; however, the mechanism through which this protection occurs remained elusive. Considering 
protective doses of MTM affected the expression of class 1 HDACs whereas the non-protective analog 
PreB did not and that these same protective doses inhibited Myc expression, we decided to test 
whether knock down of Myc affected HDAC expression levels. Indeed, we find that like MTM, Myc 
inhibition leads to a reduction in class I HDAC protein levels (Figure 4). This suggests that Myc 
regulation of HDAC expression contributes to its toxic effect in neurons exposed to oxidative  
stress. This is particularly relevant in the case of HDAC2 [15] and HDAC3 [14,30] already shown to 
be sufficient to induce toxicity in models of neurodegeneration and to negatively affect plasticity for 
brain recovery. 
Figure 4. MTM affects class 1 HDAC expression levels. 
 
(A) Western blot analysis reveals that Myc knockdown using ShRNA significantly affects class I 
HDAC protein levels. (B) Quantification of Western blots. Statistical analysis was conducted by 
1way ANOVA followed by the Dunnett post test. Significant levels compared to control shRNA 
alone. * p < 0.05; and ** p < 0.01; and *** p < 0.0001. 
4. Discussion 
MTM is not only a FDA approved chemotherapeutic agent, but also one of the most 
neuroprotective agents in vitro [2,4] and in vivo [2,5]. It mediates neuroprotection by inhibiting Sp1 
binding to it target sites in the promoters of oncogenes such as Myc, without affecting its binding to 
the promoters of tumor suppressors such as p21waf1/cip1 [2]. Considering that both MTM and HDACi 
inhibit cancer cell growth as well protect post-mitotic neurons against multiple stresses including 
oxidative stress and DNA damage [2,4,20,23], we decided to test whether these two classes of 
compounds mediate their functions by affecting similar or independent pathways. We show that MTM 
and the class 1 HDACi sodium butyrate protect cells by targeting similar pathways (Figure 1). Indeed, 
HDACi inhibit the expression of the Myc oncogene and induce the p21waf1/cip1 tumor suppressor 
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(Figures 2A–D). The induction of p21waf1/cip1 expression occurs by inducing binding of the Sp1 
activator to its site in the p21waf1/cip1 promoter (Figure 2F); on the other hand, HDACi treatment does 
not affect Sp1 binding on the Myc promoter. There are multiple Sp1 sites in the Myc promoter. We 
only tested the ones that have previously been shown to be responsive to MTM treatment [2]. It 
remains possible that Sp1 binding to different sites may be modulated by HDACi treatment. 
Alternatively, HDACi may affect Myc expression independent of Sp1. Results from cancer cell lines 
reveal that sodium butyrate inhibits Myc expression and implicate HDAC3 in this process. Indeed, 
both sodium butyrate and stable knockdown of HDAC3 in colon cancer cells leads to reduction in Myc 
levels by stimulating membrane localization of β-catenin, a Wnt pathway effector whose nuclear 
localization is necessary for Myc expression [27]. Recent evidence from rat cortical neurons also 
reveals that HDACi can cause cellular redistribution and reorganization of corepressor complexes [31]. 
Alternatively, HDACi may mediate Myc down-regulation by modulating the acetylation status of p53 
and its DNA binding [32]. 
The overlap between the pathways targeted by MTM and HDACi does not end with the modulation 
of Myc and p21waf1/cip1 levels. MTM treatment affects the expression level of HDACs themselves at 
multiple levels (Figure 3). For example, a reduction in the protein levels of all class 1 HDACs is 
observed with protective doses of MTM even though the reduction is only significant for HDAC2 and 
HDAC3. These two HDACs are particularly interesting because they mediate neuronal degeneration 
and death in multiple paradigms. HDAC2 negatively modulates memory formation and synaptic 
plasticity [15]. Indeed, neurotrophic factors such as BDNF stimulate S-nitrosylation of HDAC2. This 
in turn leads to its release from the promoters of genes leading to chromatin remodeling and to 
activation of genes involved in neuronal development [33]. Moreover, HDAC2 interacts with ATM 
and inhibits its function leading to neuronal cell cycle reentry and degeneration in ataxia [34]. 
Similarly, HDAC3 mediates toxicity in a Caenorhabditis elegans model of Huntington’s Disease [30] as 
well as in in vitro models of neuronal oxidative death [14]. HDAC3 is also a negative regulator of  
long-term memory formation [16,35]. One interesting observation is the lack of correlation between the 
MTM induced changes in HDAC mRNA and protein levels. For example, only HDAC2 is significantly 
reduced at both the mRNA and protein levels. HDAC1 and 3 are not transcriptionally affected, yet we 
observe a decline in protein levels suggesting that MTM might regulate these HDACs at post-
transcriptional or translational level. Even though, MTM treatment affects the expression of multiple 
HDACs, it does not affect global histone acetylation (Figure 3G). These results however don’t negate 
the potential of locus specific and modification specific changes such as increases in the acetylation of 
histone H4-K12 as observed in HDAC3 knockdowns [27]. In addition, even though our results 
highlight the neuroprotective benefit of inhibiting class I HDAC activity or protein levels, they do not 
rule out the importance of class II HDACs in neuron death. Indeed, inhibition of HDAC6 protects 
immature cortical neurons from oxidative stress mediated death and promotes regeneration [36].  
Our results highlight the complexity of interaction between Myc and HDACs in cells. We find that 
HDACi not only affect Myc expression, but also that Myc reduction inhibits all class 1 HDACs. This 
can happen at multiple levels. Myc has been shown to transcriptionally activate the expression of 
HDAC2 [13,29]. How it affects the rest of the identified HDACs remains to be determined. In 
addition, in agreement with this complexity, our results reveal that HDACi not only affect HDAC 
activity in the cells, but through their regulation of Myc levels, they also affect HDAC protein levels.  
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Our studies highlight the intersection between the pathways that mediate cancer and 
neurodegeneration. Indeed, we provide support for the notion that both HDACi and MTM promote 
neuroprotection by inhibiting the expression or functions of proteins that mediate transformation such 
as Myc, HDAC1, HDAC2 and HDAC3 [2,10-13] and by promoting the expression of tumor 
suppressors such as p21waf1/cip1. 
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